7254-12-8

Basic information

• Product Name: 2-(morpholin-4-ylmethyl)pyridin-3-ol
• CAS NO: 7254-12-8
• Molecular Formula: C₁₀H₁₄N₂O₂
• Molecular Weight: 194.2304
• Mol File: 7254-12-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 380.9°C at 760 mmHg
• Flash Point: 184.2°C
• Density: 1.225g/cm³
• Vapor Pressure: 2.41E-06mmHg at 25°C
• Refractive Index: 1.58
• CAS DataBase Reference: 2-(morpholin-4-ylmethyl)pyridin-3-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(morpholin-4-ylmethyl)pyridin-3-ol(7254-12-8)
• EPA Substance Registry System: 2-(morpholin-4-ylmethyl)pyridin-3-ol(7254-12-8)

Safety Data

• Hazardous Substances Data: 7254-12-8(Hazardous Substances Data)

Usage

Type of Compound

Heterocyclic compound

Components

Contains a morpholine group and a pyridine ring

Usage

Building block for the synthesis of various drugs in the pharmaceutical industry

Therapeutic Applications

Potential use in the treatment of neurological and cardiovascular disorders

Mechanism of Action

Modulates certain receptors and enzymes in the body

Additional Properties

Studied for potential antioxidant and anti-inflammatory properties

Importance

Versatile structure and potential pharmacological activities make it an important compound for medicinal and chemical research.

Upstream product

• 110-91-8 morpholine 
• 109-00-2 3-HYDROXYPYRIDINE 
• 50-00-0 formaldehyd 

Relevant articles and documents

HETEROAROMATIC ELECTROPHILES AND METHODS OF USING THEREOF

Disclosed herein are compounds, compositions, and methods for reactivating or realkylating aged acetylcholinesterase inhibited by or conjugated to the organophosphorus compound. The organophosphorus compound can be a nerve agent. The acetylcholinesterase can be in the central nerve system (CNS) and/or the peripheral nervous system (PNS) of a subject. Accordingly, methods for ameliorating, diminishing, reversing, treating or preventing the toxic effects of an organophosphorus compound in a subject are provided herein. Methods for prophylactic or therapeutic treatment of exposure to an organophosphorus nerve agent are also provided.

THIAZOLIDINONE COMPOUNDS AND USE THEREOF

A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.